Administrative Frequency of Vitiligo and Clinical Characteristics in a Colombian HMO: A Real World Data Characterization From 2015 to 2023
Author(s)
Luz E. Perez Jaramillo, MSc1, Juan Manuel Reyes Sanchez, MSc2, Farley Gonzalez, MSc1, Julian Espitia, MD2, Carlos Bello, Pharm1, Jhon E. Bolaños, MSc, MD1, Jair A. Arciniegas, MSc2, Andreina J. Alamo, BSc2, Mónica García, MSc2, Luisa Amador, MD2, Alejandra Toro, MD1;
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To estimate the administrative frequency of vitiligo and measure its demographic and clinical characteristics in a Colombian Health Maintenance Organization (HMO) between 2015 and 2023.
METHODS: A retrospective, descriptive and cohort study of patients with vitiligo between 2015 and 2023 was conducted. Patients with an ICD-10th code related to vitiligo (L80.X) were included in the study. The index date was defined as the time when the patient is diagnosed vitiligo and they were followed until death, HMO insurance discontinuation (patient loss), 5-year follow-up, or the end of the observation period (31 December 2023), whichever occurred first. Patient demographics, disease subtype, comorbidities, treatment and medical care were assessed at index, in addition treatment and medical care were evaluated as well during follow-up. All data were extracted from the HMO administrative health records.
RESULTS: A total of 21,457 patients were included in the study, most of them were adults (79.3%) - especially between 18 and 44 years old (43.8%), female (56.3%), about 25.9% recognized as mestizoes and as common comorbidities primary hypertension (25.1%), allergic rhinitis (21.3%), dyslipidemia (20.4%), anxiety disorders (19.7%), and obesity (18.1%) were found. The administrative prevalence of vitiligo exhibited an upward trend, starting at 498.5 per 100,000 persons in 2015. Despite being impacted by the COVID pandemic in 2020, which saw a rate of 477.4 per 100,000, the growth trajectory continued, peaking in 2023 at 537.0 per 100,000. On the other hand, the administrative incidence, showed a downward pattern, in 2015 was 69.8 per 100,000 and in 2023 dropped to 61.3.
CONCLUSIONS: The majority of patients with vitiligo were females, working-age adults and had as main comorbidity anxiety disorders. The annual administrative prevalence has been growing consistently since 2015 while the administrative incidence has been declining since that year.
METHODS: A retrospective, descriptive and cohort study of patients with vitiligo between 2015 and 2023 was conducted. Patients with an ICD-10th code related to vitiligo (L80.X) were included in the study. The index date was defined as the time when the patient is diagnosed vitiligo and they were followed until death, HMO insurance discontinuation (patient loss), 5-year follow-up, or the end of the observation period (31 December 2023), whichever occurred first. Patient demographics, disease subtype, comorbidities, treatment and medical care were assessed at index, in addition treatment and medical care were evaluated as well during follow-up. All data were extracted from the HMO administrative health records.
RESULTS: A total of 21,457 patients were included in the study, most of them were adults (79.3%) - especially between 18 and 44 years old (43.8%), female (56.3%), about 25.9% recognized as mestizoes and as common comorbidities primary hypertension (25.1%), allergic rhinitis (21.3%), dyslipidemia (20.4%), anxiety disorders (19.7%), and obesity (18.1%) were found. The administrative prevalence of vitiligo exhibited an upward trend, starting at 498.5 per 100,000 persons in 2015. Despite being impacted by the COVID pandemic in 2020, which saw a rate of 477.4 per 100,000, the growth trajectory continued, peaking in 2023 at 537.0 per 100,000. On the other hand, the administrative incidence, showed a downward pattern, in 2015 was 69.8 per 100,000 and in 2023 dropped to 61.3.
CONCLUSIONS: The majority of patients with vitiligo were females, working-age adults and had as main comorbidity anxiety disorders. The annual administrative prevalence has been growing consistently since 2015 while the administrative incidence has been declining since that year.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EPH170
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)